Adjuvant Chemotherapy for High-Risk Stage II Colon Cancer: A Population-Based Study

被引：0

作者：

Annmarie Butare ^{[1
]}

Tia Sutton ^{[1
]}

Elizabeth Kantzler ^{[1
]}

Katie N. Kennedy ^{[2
]}

Dmitry Tumin ^{[3
]}

Michael D. Honaker ^{[4
]}

机构：

[1] Carolina University,Department of Surgery, Brody School of Medicine at East

[2] Brody School of Medicine at East Carolina University,Department of Hematology and Oncology

[3] East Carolina University Brody School of Medicine,Department of Academic Affairs

[4] East Carolina University,Department of Surgery, Division of Surgical Oncology, Division of Surgical Oncology

来源：

Journal of Gastrointestinal Cancer | 2025年 / 56卷 / 1期

关键词：

Adjuvant chemotherapy; Stage II colon cancer; High risk;

D O I：

10.1007/s12029-025-01186-z

中图分类号：

学科分类号：

摘要：

引用

共 50 条

[21] Cost-effectiveness of adjuvant chemotherapy for high-risk stage II and stage III colon cancer in South Africa
Tan, Sarah Xinhui
Pumpalova, Yoanna
Rogers, Alexandra M. M.
Bhatt, Kishan
Herbst, Candice-lee
Ruff, Paul
Neugut, Alfred I. I.
Hur, Chin
CANCER MEDICINE, 2023, 12 (14): : 15515 - 15529
[22] Identification of patients with high-risk stage II colon cancer for adjuvant therapy
Quah, Hak-Mien
Chou, Joanne F.
Gonen, Mithat
Shia, Jinru
Schrag, Deborah
Landmann, Ron G.
Guillem, Jose G.
Paty, Philip B.
Temple, Larissa K.
Wong, W. Douglas
Weiser, Martin R.
DISEASES OF THE COLON & RECTUM, 2008, 51 (05) : 503 - 507
[23] Adjuvant Chemotherapy Use and Outcomes of Patients With High-Risk Versus Low-Risk Stage II Colon Cancer
Kumar, Aalok
Kennecke, Hagen F.
Renouf, Daniel J.
Lim, Howard J.
Gill, Sharlene
Woods, Ryan
Speers, Caroline
Cheung, Winson Y.
CANCER, 2015, 121 (04) : 527 - 534
[24] Adjuvant Therapy for High-Risk Stage II or III Colon Adenocarcinoma: A Propensity Score-Matched, Nationwide, Population-Based Cohort Study
Chang, Chia-Lun
Yuan, Kevin Sheng-Po
Wu, Alexander T. H.
Wu, Szu-Yuan
CANCERS, 2019, 11 (12)
[25] The effects of oxaliplatin-based adjuvant chemotherapy in high-risk stage II colon cancer with mismatch repair-deficient: a retrospective study
Liao, Leen
Tang, Jinghua
Hong, Zhigang
Jiang, Wu
Li, Yuan
Kong, Lingheng
Han, Kai
Hou, Zhenlin
Zhang, Chenzhi
Zhou, Chi
Zhang, Linjie
Sui, Qiaoqi
Xiao, Binyi
Mei, Weijian
Yu, Jiehai
Yang, Wanjun
Pan, Zhizhong
Ding, Pei-Rong
BMC CANCER, 2024, 24 (01)
[26] The effects of oxaliplatin-based adjuvant chemotherapy in high-risk stage II colon cancer with mismatch repair-deficient: a retrospective study
Leen Liao
Jinghua Tang
Zhigang Hong
Wu Jiang
Yuan Li
Lingheng Kong
Kai Han
Zhenlin Hou
Chenzhi Zhang
Chi Zhou
Linjie Zhang
Qiaoqi Sui
Binyi Xiao
Weijian Mei
Jiehai Yu
Wanjun Yang
Zhizhong Pan
Pei-Rong Ding
BMC Cancer, 24
[27] Do high-risk features support the use of adjuvant chemotherapy in stage II colon cancer? A Turkish Oncology Group study
Artac, Mehmet
Turha, Nazim Serdar
Kocer, Murat
Karabulut, Bulent
Bozcuk, Hakan
Yalcin, Suayip
Karaagac, Mustafa
Gunduz, Seyda
Isik, Nalan
Uygunl, Kazinn
TUMORI JOURNAL, 2014, 100 (02): : 143 - 148
[28] Study of a High-Risk Group of Stage II Colon Cancer
Hirosawa, Tomoichiro
Itabashi, Michio
Bamba, Yoshiko
Ogawa, Shinpei
Sirotani, Noriyasu
Kameoka, Shingo
INTERNATIONAL SURGERY, 2009, 94 (02) : 130 - 135
[29] Is the benefit of adjuvant chemotherapy limited to high-risk stage ii colorectal cancer?
Roberto, M.
Romiti, A.
Pilozzi, E.
Balducci, G.
Ferri, M.
Uccini, S.
Falcone, R.
Campisi, G.
Mercantini, P.
Mazzuca, F.
Di Pietro, F. R.
Onesti, C. E.
Botticelli, A.
Marchetti, P.
ANNALS OF ONCOLOGY, 2016, 27
[30] Prognostic model for predicting the survival benefit of adjuvant chemotherapy for elderly patients with stage II colon cancer: a population-based study
Yu, Guanhua
Wei, Ran
Liu, Hengchang
Liu, Yixiao
Guan, Xu
Wang, Xishan
Jiang, Zheng
EUROPEAN JOURNAL OF CANCER PREVENTION, 2024, 33 (02) : 105 - 114

← 1 2 3 4 5 →